The Biotech Revaluation Is On

 | Apr 17, 2013 | 6:20 AM EDT  | Comments
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

gild

,

biib

,

celg

,

regn

,

lly

,

gsk

,

azn

They came right back yesterday. It was as if they didn't skip a beat, aided by the fine results by Johnson & Johnson (JNJ) and Coca-Cola (KO).

It was as if they had a Food and Drug Administration buy program. Of course, the yield hunters went right after stock like Eli Lilly (LLY) and GlaxoSmithKline (GSK) and the now perennial 52-week-high AstraZeneca (AZN), the latter totally undeserving of the honor given its poor performance of its actual business as opposed to its stock.

But what I find so astounding isn't the strength in the classic, somewhat high-yielding soft goods stocks but the amazing resilience of the stocksthatgoupeveryday. I am making that one word, because it is the new title I am using for Gilead Sciences (GILD), Biogen Idec (BIIB), Celgene (CELG) and, perhaps most stunningly, Regeneron Pharmaceuticals (REGN).

Now each of these companies has some terrific drugs in the works. There are novel formulations and terrific pipelines. That's terrific, but I have to tell you that this everyday revaluation -- one I warned you about when I suggested you buy calls on these stocks -- is pretty stunning.

Regeneron in particular, is most amazing. It has a terrific ophthalmological pipeline as well as the blockbuster Eylea, and it has a potential for a brand-new anti-cholesterol franchise that isn't based on statins, for those who can't tolerate them.

Everyone wants yield because of the scarcity of bonds that give you anywhere near even the reduced yields that Procter & Gamble (PG) and Clorox (CLX) give you.

But what the growth mutual funds want is growth that can't be pinned down and isn't even crimped by European formulations, which had been the worry for, say, Celgene not that long ago. And these four horsemen have it.

Perhaps the best way to think about this is to recognize that these stocks are the anti-gold. Anything that could drive up gold is bad for biotech. Anything that can drive it down is good. So next time you see gold swoon and take down the whole market, we now know the total handbook for the moment: Buy more deep-in-the-money calls on Biogen Idec, Gilead Sciences, Celgene and Regeneron.

These four stocks remain THE go-to stocks on any geopolitical/terror weakness in this market.

Random musings: You can see these biotech animal spirits at work on a smaller scale in Acorda Therapeutics (ACOR), which reported a potential, just a potential, breakthrough in stroke treatment, where some of the losses from a stroke might be able to be rolled back. That stock, ACOR, was up $4 today after being up almost $4 yesterday on the breakthrough. Frankly, the news is so breathtaking, I still don't think the move is over yet.

Columnist Conversations

GS has cleared the important hurdle on the way up which increases the odds for an eventual rally towards the 1...
A good quarterly report has sent shares of Calamos Asset Management (CLMS) sharply higher. CLMS was up about ...
Electronics distributor Ingram Micro (IM) reported better than 16% growth in its Q3 sending the stock up about...
Market posting decent day considering Ebola getting headlines again. Believe investors have learned not to pa...

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.